How much will Moderna pay in the settlement?

Moderna will pay up to $2.25 billion to Genevant and Arbutus Biopharma, including an upfront payment and a contingent amount.

What is Moderna's future focus after the settlement?

After the settlement, Moderna will focus on its pipeline of cancer vaccines, with key oncology readouts expected in 2026.

Home / Business and Economy / Moderna Settles Patent Dispute, Eyes Cancer Vaccines

Moderna Settles Patent Dispute, Eyes Cancer Vaccines

Q: What legal battle did Moderna settle?

Moderna settled a long-standing legal dispute over the lipid nanoparticle technology used in its COVID-19 vaccine.

4 Mar

•

Summary

Moderna resolves a long-standing legal dispute over COVID-19 vaccine technology.
The company will pay up to $2.25 billion to settle lawsuits with Genevant and Arbutus.
This settlement allows Moderna to refocus on its promising cancer vaccine pipeline.

Moderna Settles Patent Dispute, Eyes Cancer Vaccines

Moderna's stock experienced a notable 9% increase on Wednesday, largely attributed to the resolution of a long-standing legal dispute over the lipid nanoparticle technology essential for its COVID-19 vaccine.

The settlement involves payments potentially reaching $2.25 billion to Genevant, a subsidiary of Roivant Sciences, and Arbutus Biopharma. This agreement effectively concludes all U.S. and international legal actions that accused Moderna of unauthorized use of patented technology.